We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+8.63%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$9.44B
AUM Growth
-$323M
Cap. Flow
-$311M
Cap. Flow %
-3.3%
Top 10 Hldgs %
61.29%
Holding
95
New
24
Increased
17
Reduced
2
Closed
10

Top Buys

Rank Stock Value
1
SGP
SpyGlass Pharma
SGP
+$216M
2
WVE icon
Wave Life Sciences
WVE
+$114M
3
ZLAB icon
Zai Lab
ZLAB
+$106M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$75.5M
5
NUVL
Nuvalent
NUVL
+$66.7M

Top Sells

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$743M
2
RNAM
Avidity Biosciences
RNAM
+$623M
3
ACLX
Arcellx
ACLX
+$82.6M
4
BLTE
Belite Bio
BLTE
+$69.2M
5
IVVD icon
Invivyd
IVVD
+$42.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.71%
2 Financials 0.22%

No holdings matched the selected filter criteria.

1 2 3 4

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, RA Capital Management held 95 positions worth $9.44B, down 3.3% from $9.76B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

RA Capital Management withdrew a net $311M in Q1 2026, closing 10 positions and reducing 2 holdings. Its most notable exit was Cidara Therapeutics, an estimated $743M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

Against the trend, RA Capital Management opened a new position in SpyGlass Pharma worth $208M.

  • RA Capital Management's largest Q1 2026 buy was SpyGlass Pharma: 8,021,117 shares worth $208M.
  • RA Capital Management added most to Wave Life Sciences in Q1 2026, an estimated $114M increase.
  • RA Capital Management's biggest Q1 2026 reduction was Contineum Therapeutics, cutting an estimated $11.9M.
  • RA Capital Management fully exited Cidara Therapeutics in Q1 2026, selling an estimated $743M.
  • RA Capital Management's ten largest holdings make up 61% of its $9.44B portfolio in Q1 2026.
  • RA Capital Management opened 24 new positions and closed 10 in Q1 2026.
  • RA Capital Management's portfolio value fell 3.3% quarter-over-quarter to $9.44B.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.